2 results match your criteria: "The University of Ottawa at the Ottawa Hospital Research Institute[Affiliation]"
Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.
J Acquir Immune Defic Syndr
December 2013
*Center for Research on Inner City Health, The Keenan Research Center in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada; †Department of Medicine, University of Toronto, Toronto, Ontario, Canada; ‡Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; §Division of General Internal Medicine, St. Michael's Hospital, Toronto, Ontario, Canada; ‖VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR&D Health Economics Resource Center, Menlo Park, CA; ¶Center for Health Economics, University of York, York, United Kingdom; #Center for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia, Canada **CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada; ††School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; ‡‡VA Palo Alto Health Care System, Palo Alto, CA; §§Department of Medicine, Stanford University, Stanford, CA; ‖‖Duke Clinical Research Institute, Duke University, Durham, NC; ¶¶James J. Peters VA Medical Center, Bronx, NY; ##Department of Medicine, Mt. Sinai School of Medicine, New York, NY; ***VA Cooperative Studies Program Coordinating Center, West Haven, CT; †††MRC Clinical Trials Unit, London, United Kingdom; ‡‡‡Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; §§§The University of Ottawa at The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; and ‖‖‖Center for Primary Care and Outcomes Research and Center for Health Policy, Stanford University, Stanford, CA.
Objective: Newer antiretroviral drugs provide substantial benefits but are expensive. The cost-effectiveness of using antiretroviral drugs in combination for patients with multidrug-resistant HIV disease was determined.
Design: A cohort state-transition model was built representing treatment-experienced patients with low CD4 counts, high viral load levels, and multidrug-resistant virus.
We conducted a prospective cohort study testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in myeloid malignancies. A total of 1483 patients undergoing transplantation for myeloid malignancies (IV-BU, N = 1025; TBI, N = 458) were enrolled. Cohorts were similar with respect to age, gender, race, performance score, disease, and disease stage at transplantation.
View Article and Find Full Text PDF